Mohammed Makkiya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mohammed Makkiya has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
- Harish Ramakrishna
Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN
3 shared publications Pedro Villablanca
3 shared publicationsAgata Leśniak-Sobelga
2 shared publicationsAnna Bortnick
2 shared publicationsDavid Briceno
2 shared publications- Divyanshu Mohananey
Medical College of Wisconsin Cardiovascular Center , Milwaukee, WI
2 shared publications
Latest Publications
- Open Access
Incidence and Outcomes of Atrial Fibrillation and Systolic Dysfunction in Patients Receiving Mavacamten for Obstructive Hypertrophic Cardiomyopathy: A Multicenter Study
Importance Mavacamten is highly effective in treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) and was approved for commercial use with a risk mitigation program (REMS) to monitor the impact on left ventricular systolic function (LVSD). The impact of mavacamten on atrial fibrillation (AF) occurrence is not well characterized. Objective Determine the real-world incidence of new-onset and recurrent AF among patients with HCM treated with commercial mavacamten. Secondary objectives included assessing the incidences of LVSD, heart failure (HF), and cardiogenic shock. Design A multicenter cohort study. Center-level data were aggregated for patients who received mavacamten from May 2022 through December 2024. Setting Twenty-one outpatient HCM centers in the United States. Participants Consecutive patients ≥18 years of age with oHCM were included; those with permanent AF were excluded. Exposures At least one dose of commercial mavacamten. Main Outcomes and Measures Incidence of new-onset and recurrent AF, LVSD, HF, and cardiogenic shock. Results Among 1,538 patients (median age, 66 years [95% CI, 65.9–66.1]; 57% female [95% CI, 54–59%]), 25% [95% CI, 22-27%] had prior AF. Median mavacamten exposure was 13.4 months [95% CI, 11.8–15.0]. Overall AF incidence was 13% [95% CI, 10–17%], including 5% [95% CI, 4–7%] new-onset and 39% [95% CI, 27–51%] recurrent AF in those with history of AF prior to mavacamten initiation. LVEF Conclusions and Relevance In this multicenter cohort receiving commercial mavacamten, we identified an annual incidence of 5% new-onset AF and 39% recurrent AF, while 70% of patients who developed LVEFQuestion What are the real-world burden and consequences of atrial fibrillation (AF) in patients with hypertrophic cardiomyopathy treated with commercial mavacamten? Findings In a multicenter cohort of more than 1,500 patients, 5% experienced new-onset AF, while 39% of those with pre-existing AF experienced recurrence after mavacamten initiation. Left ventricular ejection fraction (LVEF) fell below 50% in 8% of patients, 70% of whom had concurrent AF. Meaning Real-world experience with mavacamten emphasizes that regular surveillance for AF is an important aspect of managing patients with HCM. Additionally, the identification of AF should prompt LVEF assessment and aggressive rhythm management, given the potential association between AF and decrease in LVEF. The observed incidence of AF on mavacamten highlights the need for further studies on potential mechanisms and for proactive surveillance and management strategies.
Open AccessIncidence and Outcomes of Atrial Fibrillation and Systolic Dysfunction in Patients Receiving Mavacamten for Obstructive Hypertrophic Cardiomyopathy: A Multicenter Study
Importance Mavacamten is highly effective in treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) and was approved for commercial use with a risk mitigation program (REMS) to monitor the impact on left ventricular systolic function (LVSD). The impact of mavacamten on atrial fibrillation (AF) occurrence is not well characterized. Objective Determine the real-world incidence of new-onset and recurrent AF among patients with HCM treated with commercial mavacamten. Secondary objectives included assessing the incidences of LVSD, heart failure (HF), and cardiogenic shock. Design A multicenter cohort study. Center-level data were aggregated for patients who received mavacamten from May 2022 through December 2024. Setting Twenty-one outpatient HCM centers in the United States. Participants Consecutive patients ≥18 years of age with oHCM were included; those with permanent AF were excluded. Exposures At least one dose of commercial mavacamten. Main Outcomes and Measures Incidence of new-onset and recurrent AF, LVSD, HF, and cardiogenic shock. Results Among 1,538 patients (median age, 66 years [95% CI, 65.9–66.1]; 57% female [95% CI, 54–59%]), 25% [95% CI, 22-27%] had prior AF. Median mavacamten exposure was 13.4 months [95% CI, 11.8–15.0]. Overall AF incidence was 13% [95% CI, 10–17%], including 5% [95% CI, 4–7%] new-onset and 39% [95% CI, 27–51%] recurrent AF in those with history of AF prior to mavacamten initiation. LVEF Conclusions and Relevance In this multicenter cohort receiving commercial mavacamten, we identified an annual incidence of 5% new-onset AF and 39% recurrent AF, while 70% of patients who developed LVEFQuestion What are the real-world burden and consequences of atrial fibrillation (AF) in patients with hypertrophic cardiomyopathy treated with commercial mavacamten? Findings In a multicenter cohort of more than 1,500 patients, 5% experienced new-onset AF, while 39% of those with pre-existing AF experienced recurrence after mavacamten initiation. Left ventricular ejection fraction (LVEF) fell below 50% in 8% of patients, 70% of whom had concurrent AF. Meaning Real-world experience with mavacamten emphasizes that regular surveillance for AF is an important aspect of managing patients with HCM. Additionally, the identification of AF should prompt LVEF assessment and aggressive rhythm management, given the potential association between AF and decrease in LVEF. The observed incidence of AF on mavacamten highlights the need for further studies on potential mechanisms and for proactive surveillance and management strategies.
- Open Access
- 13 May 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (10) , 2095
Speckle-Tracking Echocardiography with Novel Imaging Technique of Higher Frame Rate
Background: The accuracy of speckle-tracking echocardiography (STE) depends on temporal resolution. The goal of this study was to demonstrate the feasibility of relatively high frame rate (rHi-FR) (~200 fps) for STE. Methods: In this prospective study, echocardiographic images were acquired using clinical scanners on patients with normal left ventricular systolic function using rHi-FR and conventional frame rate (Reg-FR) (~50 FPS). GLS values were evaluated on apical 4-, 2- and 3-chamber images acquired in both rHi-FR and Reg-FR. Inter-observer and intra-observer variabilities were assessed in rHi-FR and Reg-FR. Results: There were 143 echocardiograms evaluated in this study. The frame rate of rHi-FR was 190 ± 25 and Reg-FR was 50 ± 3, and the heart rate was 71 ± 13. Absolute strain values measured in rHi-FR were significantly higher than those measured in Reg-FR (all p < 0.001). Inter-observer and intra-observer correlations were strong in both rHi-FR and Reg-FR. Conclusions: We demonstrated that absolute strain values were significantly higher using rHi-FR when compared with Reg-FR. It is plausible that higher temporal resolution enabled the measurement of myocardial strain at desired time point. Further investigations are necessary to evaluate the value of rHi-FR to assess myocardial strain in the setting of tachycardia.
- 13 May 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (10) , 2095
Open AccessSpeckle-Tracking Echocardiography with Novel Imaging Technique of Higher Frame Rate
Background: The accuracy of speckle-tracking echocardiography (STE) depends on temporal resolution. The goal of this study was to demonstrate the feasibility of relatively high frame rate (rHi-FR) (~200 fps) for STE. Methods: In this prospective study, echocardiographic images were acquired using clinical scanners on patients with normal left ventricular systolic function using rHi-FR and conventional frame rate (Reg-FR) (~50 FPS). GLS values were evaluated on apical 4-, 2- and 3-chamber images acquired in both rHi-FR and Reg-FR. Inter-observer and intra-observer variabilities were assessed in rHi-FR and Reg-FR. Results: There were 143 echocardiograms evaluated in this study. The frame rate of rHi-FR was 190 ± 25 and Reg-FR was 50 ± 3, and the heart rate was 71 ± 13. Absolute strain values measured in rHi-FR were significantly higher than those measured in Reg-FR (all p < 0.001). Inter-observer and intra-observer correlations were strong in both rHi-FR and Reg-FR. Conclusions: We demonstrated that absolute strain values were significantly higher using rHi-FR when compared with Reg-FR. It is plausible that higher temporal resolution enabled the measurement of myocardial strain at desired time point. Further investigations are necessary to evaluate the value of rHi-FR to assess myocardial strain in the setting of tachycardia.
- 16 October 2018
- Published by Wiley in Echocardiography
- Vol. 35 (11) , 1872-1877
Starfish in the heart: Congenital anomaly of the papillary muscles
Most common congenital anatomical abnormalities of the subvalvular apparatus (papillary muscles and chordae tendineae) are parachute or parachute like mitral valve. This is more commonly reported among the pediatric population as they develop heart failure symptoms shortly after birth. Reports of adult cases are rare and incidental. Multimodality imaging has an important role in evaluating such anatomical abnormalities, and identification of possible related complications. We are describing a rare atypical variant of parachute like mitral valve.
- 16 October 2018
- Published by Wiley in Echocardiography
- Vol. 35 (11) , 1872-1877
Starfish in the heart: Congenital anomaly of the papillary muscles
Most common congenital anatomical abnormalities of the subvalvular apparatus (papillary muscles and chordae tendineae) are parachute or parachute like mitral valve. This is more commonly reported among the pediatric population as they develop heart failure symptoms shortly after birth. Reports of adult cases are rare and incidental. Multimodality imaging has an important role in evaluating such anatomical abnormalities, and identification of possible related complications. We are describing a rare atypical variant of parachute like mitral valve.
- 1 December 2016
- Published by Elsevier in International Journal of Cardiology
- Vol. 225, 234-243
A meta-analysis and meta-regression of long-term outcomes of transcatheter versus surgical aortic valve replacement for severe aortic stenosis
- 1 December 2016
- Published by Elsevier in International Journal of Cardiology
- Vol. 225, 234-243
A meta-analysis and meta-regression of long-term outcomes of transcatheter versus surgical aortic valve replacement for severe aortic stenosis